A clinical trial to investigate the triple combination of GLPG-2451, GLPG-2222 and GLPG-2737
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GLPG 2222 (Primary) ; GLPG 2451 (Primary) ; GLPG 2737 (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 02 Jan 2018 According to a Galapagos NV media release, the company expects to dose the first patient in the first quarter of 2018 and an interim readout from this study is expected in the summer of 2018.
- 27 Jun 2017 New trial record
- 20 Jun 2017 According to a Galapagos media release, this trial is expected to begin in Q4 2017.